Seegene and Eisai's Eidia Partner on MDx Tests in Japan | GenomeWeb

Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.

Under the agreement, Eidia gains access to Seegene's portfolio of multiplexed molecular diagnostics tests based on the company's tagging oligonucleotide capture and extension, or TOCE, technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.